Can small molecule GLP-1 agonists be the next first-line drugs in type-2 diabetes mellitus?

Q3 Pharmacology, Toxicology and Pharmaceutics

Journal of Basic and Clinical Physiology and Pharmacology Pub Date : 2023-12-05 eCollection Date: 2024-01-01 DOI:10.1515/jbcpp-2023-0234

Rajmohan Seetharaman, Swarnima Pandit

引用次数: 0

查看原文本刊更多论文

小分子GLP-1激动剂能否成为治疗2型糖尿病的下一个一线药物?

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Basic and Clinical Physiology and Pharmacology Pharmacology, Toxicology and Pharmaceutics-Pharmacology

CiteScore

3.90

自引率

0.00%

发文量

期刊介绍： The Journal of Basic and Clinical Physiology and Pharmacology (JBCPP) is a peer-reviewed bi-monthly published journal in experimental medicine. JBCPP publishes novel research in the physiological and pharmacological sciences, including brain research; cardiovascular-pulmonary interactions; exercise; thermal control; haematology; immune response; inflammation; metabolism; oxidative stress; and phytotherapy. As the borders between physiology, pharmacology and biochemistry become increasingly blurred, we also welcome papers using cutting-edge techniques in cellular and/or molecular biology to link descriptive or behavioral studies with cellular and molecular mechanisms underlying the integrative processes. Topics: Behavior and Neuroprotection, Reproduction, Genotoxicity and Cytotoxicity, Vascular Conditions, Cardiovascular Function, Cardiovascular-Pulmonary Interactions, Oxidative Stress, Metabolism, Immune Response, Hematological Profile, Inflammation, Infection, Phytotherapy.